New role for an established drug? Bisphosphonates as potential anticancer agents

Prostate Cancer and Prostatic Diseases

Volumn 15, Issue 2, 2012, Pages 111-119

  Koul, H K ^a   Koul, S ^a   Meacham, R B ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

anticancer; bisphosphonates; zoledronic acid

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; DENOSUMAB; DOCETAXEL; DOXORUBICIN; IBANDRONIC ACID; MEVALONIC ACID; NITROGEN CONTAINING BIPHOSPHONATE; PLACEBO; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR ANTIBODY; PROTEIN ANTIBODY; RISEDRONIC ACID; STRONTIUM 89; UNCLASSIFIED DRUG; VASCULOTROPIN; ZOLEDRONIC ACID;

ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BONE METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG BINDING; DRUG DOSE INCREASE; DRUG EFFECT; DRUG POTENTIATION; DRUG RESEARCH; DRUG SAFETY; HUMAN; HYPOCALCEMIA; IMMUNOSTIMULATION; LUNG NON SMALL CELL CANCER; METASTASIS; METASTASIS INHIBITION; MICROMETASTASIS; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NONHUMAN; OSTEOLYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; RECURRENT CANCER; RETROSPECTIVE STUDY; REVIEW; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE AND BONES; BONE DENSITY; BONE NEOPLASMS; BONE RESORPTION; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; CLINICAL TRIALS AS TOPIC; DIPHOSPHONATES; DRUG SYNERGISM; FEMALE; HUMANS; IMIDAZOLES; MALE; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; OSTEOCLASTS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 84861231508     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2011.41     Document Type: Review

References (78)

1. American Cancer Society. Global Cancer Facts & Figures 2007. American Cancer Society: Atlanta, GA, 2007
2. American Cancer Society. Cancer Facts & Figures 2010. American Cancer Society: Atlanta, GA, 2010
3. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prostate cancer, v.3.2010. http://www.nccn.org
4. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001; 27: 165-176
5. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96: 879-882
6. Lipton A, Small E, Saad F, Gleason D, Gordon D, Smith M et al. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer Invest 2002; 20 (Suppl): 45-54
7. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458-1468
8. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003; 98: 1735-1744
9. Pavlakis N, Schmidt RL, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2005; (3): CD003474
10. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001; 296: 235-242
11. Green JR. Bisphosphonates: preclinical review. Oncologist 2004; 9 (Suppl 4): 3-13
12. Zometa (Zoledronic Acid) Injection [package insert], Novartis Pharmaceuticals: East Hanover, NJ, 2011. http://www.accessdata. fda.gov/drugsatfda-docs/label/2009/021223s021018lbl.pdf
13. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889; 1: 571-573
14. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002; 2: 584-593
15. Winter MC, Holen I, Coleman RE. Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev 2008; 34: 453-475
16. Fritz G. Targeting the mevalonate pathway for improved anticancer therapy. Curr Cancer Drug Targets 2009; 9: 626-638
17. Green JR, Muller K, Jaeggi KA. Preclinical pharmacology of CGP 420446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 1994; 9: 745-751
18. Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, Colombel M et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000; 60: 2949-2954
19. Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002; 62: 6538-6544
20. Corey E, Brown LG, Quinn JE, Poot M, Roudier MP, Higano CS et al. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res 2003; 9: 295-306
21. Coxon JP, Oades GM, Kirby RS, Colston KW. Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation. BJU Int 2004; 94: 164-170
22. Neville-Webbe HL, Rostami-Hodjegan A, Evans CA, Coleman RE, Holen I. Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer 2005; 113: 364-371
23. Morgan C, Lewis PD, Jones RM, Bertelli G, Thomas GA, Leonard RC. The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer. Acta Oncol 2007; 46: 669-677
24. Koul HK, Koul S, Kumar B, Meacham RB, Maroni P. Direct effects of zoledronic acid on hormone-responsive and hormone-refractory prostate cancer cells. Presented at: ASCO Genitourinary Cancers Symposium; 5-7 March 2010; San Francisco, CA (abstract 184)
25. Russell MR, Liu Q, Fatatis A. Targeting the a receptor for platelet-derived growth factor as a primary or combination therapy in a preclinical model of prostate cancer skeletal metastasis. Clin Cancer Res 2010; 16: 5002-5010
26. Ullen A, Lennartsson L, Harmenberg U, Hjelm-Eriksson M, Kalkner KM, Lennernas B et al. Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid. Acta Oncol 2005; 44: 644-650
27. Coscia M, Quaglino E, Iezzi M, Curcio C, Pantaleoni F, Riganti C et al. Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J Cell Mol Med 2010; 14: 2803-2815
28. Roelofs AJ, Coxon FP, Ebetino FH, Lundy MW, Henneman ZJ, Nancollas GH et al. Fluorescent risedronate analogs reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo. J Bone Miner Res 2010; 25: 606-616
29. Marra M, Salzano G, Leonetti C, Tassone P, Scarsella M, Zappavigna S et al. Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes. Nanomedicine 2011 (e-pub ahead of print)
30. Denoyelle C, Hong L, Vannier JP, Soria J, Soria C. New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects. Br J Cancer 2003; 88: 1631-1640
31. Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002; 302: 1055-1061
32. Benzaid I, Monkkonen H, Stresing V, Bonnelye E, Green J, Monkkonen J et al. Zoledronic acid-induced IPP/ApppI (phosphoantigen) accumulation in human breast cancer cells correlates with Vg9Vd2 T cell-mediated cancer cell death in vitro and in vivo. Presented at: 2nd International Bone and Mineral Society Davos Workshop: Bone Biology & Therapeutics; 14-19 March 2010; Davos, Switzerland (abstract 93)
33. Jameson JM, Cruz J, Costanzo A, Terajima M, Ennis FA. A role for the mevalonate pathway in the induction of subtype cross-reactive immunity to influenza A virus by human gammadelta T lymphocytes. Cell Immunol 2010; 264: 71-77
34. Monkkonen H, Kuokkanen J, Holen I, Evans A, Lefley DV, Jauhiainen M et al. Bisphosphonate-induced ATP analog formation and its effect on inhibition of cancer cell growth. Anticancer Drugs 2008; 19: 391-399
35. Roelofs AJ, Jauhiainen M, Monkkonen H, Rogers MJ, Monkkonen J, Thompson K. Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP. Br J Haematol 2009; 144: 245-250
36. Thompson K, Roelofs AJ, Jauhiainen M, Monkkonen H, Monkkonen J, Rogers MJ. Activation of gammadelta T cells by bisphosphonates. Adv Exp Med Biol 2010; 658: 11-20
37. Giraudo E, Inoue M, Hanahan D. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 2004; 114: 623-633
38. Dieli F, Vermijlen D, Fulfaro F, Caccamo N, Meraviglia S, Cicero G et al. Targeting human gd T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res 2007; 67: 7450-7457
39. Lipton A, Cook R, Saad F, Major P, Garnero P, Terpos E et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 2008; 113: 193-201
40. Facchini G, Caraglia M, Morabito A, Marra M, Piccirillo MC, Bochicchio AM et al. Metronomic administration of zoledronic acid and taxotere combination in castration resistant prostate cancer patients: Phase I ZANTE trial. Cancer Biol Ther 2010; 10: 543-548
41. Wu EQ, Guo A, Shi L, Lu M, Yu AP, Sharma H et al. Comparing early intervention with zoledronic acid to no bisphosphonate (BP) therapy in patients with metastatic prostate cancer to bone: a study of the US Veterans Affairs (VA) population. Presented at: CABS 10th International Meeting; 22-25 September 2010; Sheffield, U.K.
42. Naoe M, Ogawa Y, Takeshita K, Morita J, Shichijo T, Fuji K et al. Zoledronate stimulates gamma delta T cells in prostate cancer patients. Oncol Res 2010; 18: 493-501
43. Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B et al. Denosumab to prolong bone metastasis-free survival in men with castrate-resistant prostate cancer: results of a global phase 3, randomized, double-blind trial. Plenary presentation at the AUA 2011 Annual Meeting; 14-19 May 2011; Washington, D.C.
44. Norton L, Massague J. Is cancer a disease of self-seeding? Nat Med 2006; 12: 875-878
45. Meads MB, Hazlehurst LA, Dalton WS. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res 2008; 14: 2519-2526
46. Shiozawa Y, Havens AM, Pienta KJ, Taichman RS. The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites. Leukemia 2008; 22: 941-950
47. Aft R, Naughton M, Trinkaus K, Watson M, Ylagan L, Chavez- Macgregor M et al. Effect of zoledronic acid on the development of bone marrow metastases and bone turnover in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol 2010; 11: 421-428
48. Lin AY, Park JW, Scott J, Melisko M, Goga A, Moasser MM et al. Zoledronic acid as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells in bone marrow. J Clin Oncol 2008; 26 (Suppl): 20s (abstract 559)
49. Rack B, Juckstock J, Genss EM, Schoberth A, Schindlbeck C, Strobl B et al. Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer. Anticancer Res 2010; 30: 1807-1813
50. Solomayer EF, Gebauer G, Hirnle P, Janni W, Luck HJ, Becker S et al. Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients. Presented at: 31st Annual San Antonio Breast Cancer Symposium; 10-14 December 2008; San Antonio, TX (abstract 2048)
51. Berg A, Berner A, Lilleby W, Bruland OS, Fossa SD, Nesland JM et al. Impact of disseminated tumor cells in bone marrow at diagnosis in patients with nonmetastatic prostate cancer treated by definitive radiotherapy. Int J Cancer 2007; 120: 1603-1609
52. Kollermann J, Weikert S, Schostak M, Kempkensteffen C, Kleinschmidt K, Rau T et al. Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment. J Clin Oncol 2008; 26: 4928-4933
53. Morgan TM, Lange PH, Porter MP, Lin DW, Ellis WJ, Gallaher IS et al. Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence. Clin Cancer Res 2009; 15: 677-683
54. Danila DC, Heller G, Gignac GA, Gonzalez-Espinoza R, Anand A, Tanaka E et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 2007; 13: 7053-7058
55. Scher HI, Pantel K. Bone marrow aspiration for disseminated tumor cell detection: a must-have test or is the jury still out? J Clin Oncol 2009; 27: 1531-1533
56. Santini D, Martini F, Fratto ME, Galluzzo S, Vincenzi B, Agrati C et al. In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients. Cancer Immunol Immunother 2009; 58: 31-38
57. Santini D, Vincenzi B, Galluzzo S, Battistoni F, Rocci L, Venditti O et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res 2007; 13 (15 Pt 1): 4482-4486
58. Rodrigues P, Hering F. Adjuvant effect of IV clodronate on delay of bone metastasis in high-risk prostate cancer patients: a prospective study. Ann Oncol 2010; 21 (Suppl 8): viii280 (abstract 895P)
59. Dearnaley DP, Mason MD, Parmar MK, Sanders K, Sydes MR. Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol 2009; 10: 872-876
60. Brufsky AM, Bosserman LD, Caradonna RR, Haley BB, Jones CM, Moore HC et al. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer 2009; 9: 77-85
61. Eidtmann H, de Boer R, Bundred N, Llombart-Cussac A, Davidson N, Neven P et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol 2010; 21: 2188-2194
62. Llombart A, Frassoldati A, Paija O, Sleeboom HP, Jerusalem G, Mebis J et al. Zoledronic acid prevents aromatase inhibitorassociated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: E-ZO-FAST 36-month follow-up. Presented at: ASCO 2009 Breast Cancer Symposium; 8-10 October 2009; San Francisco, CA (abstract 213)
63. Frassoldati A, Brufsky A, Bundred N, Lambert-Falls R, Hadji P, Schenk N et al. Effect of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: a 24-month integrated follow-up of the Z-FAST/ZO-FAST trials. Presented at: 11th International Conference on Primary Therapy of Early Breast Cancer; 11-14 March 2009; St Gallen, Switzerland (abstract 132)
64. De Boer R, Bundred N, Eidtmann H, Llombart A, Neven P, von Minckwitz G et al. The effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: the ZO-FAST study 5-year final follow-up. Presented at: 33rd Annual San Antonio Breast Cancer Symposium; 8-12 December 2010; San Antonio, TX (poster P5-11-01)
65. Coleman R, Bundred N, de Boer R, Llombart A, Campbell I, Neven P et al. Impact of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST. Presented at: 32nd Annual San Antonio Breast Cancer Symposium; 9-13 December 2009; San Antonio, TX (abstract 4082)
66. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Postlberger S, Menzel C et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009; 360: 679-691
67. Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengrueth G, Poestlberger S, Dubsky PC et al. Mature results from ABCSG-12: adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine-responsive early breast cancer. J Clin Oncol 2010; 28 (Suppl): 75s (abstract 533)
68. Coleman RE, Thorpe HC, Cameron D, Dodwell D, Burkinshaw R, Keane M et al. Adjuvant treatment with zoledronic acid in stage II/III breast cancer. The AZURE trial (BIG 01/04). Presented at: 33rd Annual San Antonio Breast Cancer Symposium; 8-12 December 2010; San Antonio, TX (abstract S4-5)
69. Coleman RE, Winter MC, Cameron D, Bell R, Dodwell D, Keane MM et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer 2010; 102: 1099-1105
70. Zaghloul MS, Boutrus R, El-Hossieny H, Kader YA, El-Attar I, Nazmy M. A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. Int J Clin Oncol 2010; 15: 382-389
71. Zarogoulidis K, Boutsikou E, Zarogoulidis P, Eleftheriadou E, Kontakiotis T, Lithoxopoulou H et al. The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis. Int J Cancer 2009; 125: 1705-1709
72. Mystakidou K, Katsouda E, Parpa E, Kelekis A, Galanos A, Vlahos L. Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline. Med Oncol 2005; 22: 195-201
73. Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 2010; 376: 1989-1999
74. Porfiri E, Collins SI, Barton D, Billingham L, McLaren DB, Nixon GG et al. Initial feasibility and safety results from a phase II/III clinical trial to evaluate docetaxel (D) therapy in combination with zoledronic acid (ZA) strontium-89 (Sr89) in hormone-refractory prostate cancer patients: ISRCTN12808747. J Clin Oncol 2010; 28 (Suppl): 385s (abstract 4677)
75. U.S. National Institutes of Health. Zoledronate plus standard therapy compared with placebo plus standard therapy to prevent bone metastases in patients with recurrent prostate cancer that has no symptoms. http://clinicaltrials.gov/ct2/ show/NCT00005073
76. U.S. National Institutes of Health. RADAR trial-randomized androgen deprivation and radiotherapy. http://clinicaltrials. gov/ct2/show/NCT00193856
77. U.S. National Institutes of Health. Androgen suppression alone or combined with zoledronate, docetaxel, prednisolone, and/or celecoxib in treating patients with locally advanced or metastatic prostate cancer. http://clinicaltrials.gov/ct2/show/ NCT00268476
78. Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377: 813-822